

Cite this: *Chem. Sci.*, 2023, 14, 1896

All publication charges for this article have been paid for by the Royal Society of Chemistry

Diastereodivergent *cis*- and *trans*-fused [4 + 2] annulations of cyclic 1,3-dienes and 1-azadienes via ligand-controlled palladium catalysis†

Yuan Hu,^a Jin-Yu Huang,^a Ru-Jie Yan,^a Zhi-Chao Chen,^{*a} Qin Ouyang,^{id b} Wei Du^{id a} and Ying-Chun Chen^{id *ab}

Despite the blossoming of reports of diastereodivergent synthesis over the past years, switchable control of the stereochemistry of the bridgehead atoms of the fused frameworks has been significantly underdeveloped. Here we disclose the ability of Pd⁰-π-Lewis base catalysis to finely reverse the concerted inverse-electron-demand aza-Diels–Alder cycloaddition reaction between cyclic 1,3-dienes and aurone-derived 1-azadienes. In contrast, the *in situ*-formed HOMO-energy-increased Pd⁰-η²-complexes of cyclic 1,3-dienes underwent a cascade vinylogous Michael addition/allylic amination process with 1-azadienes. Moreover, judicious selection of chiral ligands allowed for switchable diastereodivergent [4 + 2] annulations to be accomplished, resulting in the construction of both *cis*- and *trans*-fused tetrahydropyridine architectures in high yields with moderate to excellent stereoselectivity levels. A variety of acyclic 1,3-dienes and 1-heterodienes were also applied, and furnished a structural diversity of enantioenriched frameworks.

Received 12th December 2022

Accepted 16th January 2023

DOI: 10.1039/d2sc06813c

rsc.li/chemical-science

Introduction

As different stereoisomers usually display distinct biological activities, precise construction of multiple optically active isomers has always been an attractive but challenging task in organic chemistry and the drug discovery field.¹ Diastereodivergent synthesis, which enables producing diverse diastereomers from the same set of starting materials just by varying reaction conditions, has emerged as a flourishing area owing to its high efficiency and great versatility.² Several strategies, including tuning the catalysts,³ ligands,⁴ solvents⁵ and additives,⁶ *etc.*,⁷ have demonstrated to be useful for furnishing divergently many diastereomers with linear and cyclic structures. However, there have been few well-developed studies showing an ability to switch the stereochemistry of the bridgehead atoms in fused structures, and only a few examples have


been uncovered for constructing both *cis*- and *trans*-fused bicyclic or polycyclic frameworks (Scheme 1a).⁸

The application of cyclic alkenes as dienophile partners in a Diels–Alder cycloaddition reaction provides a very straightforward strategy to access fused skeletons; however, *cis*-fused products are usually obtained due to the inherent concerted

^aKey Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu 610041, China. E-mail: chenzhichao@scu.edu.cn; ycchen@scu.edu.cn; Fax: +86 28 85502609

^bCollege of Pharmacy, Third Military Medical University, Shapingba, Chongqing 400038, China

† Electronic supplementary information (ESI) available: Experimental procedures, spectroscopic data for new compounds, NMR and HRMS spectra, and HPLC chromatograms, CIF files of enantiopure products **4a** (CCDC 2050826), **5e** (CCDC 2219802), **11** (CCDC 2219803), **16** (CCDC 2219804), **21** (CCDC 2219805) and racemic **3a** (2050825), **17** (CCDC 2050823), **25** (CCDC 2219806). CCDC 2050823, 2050825, 2050826 and 2219802–2219806. For ESI and crystallographic data in CIF or other electronic format see DOI: <https://doi.org/10.1039/d2sc06813c>



Scheme 1 Diastereodivergent construction of *cis*- and *trans*-fused cyclic frameworks. (a) Diastereodivergent synthesis of various frameworks. (b) Uncatalysed inverse-electron-demand aza-Diels–Alder reaction. (c) Diastereodivergent [4 + 2] annulations enabled by Pd⁰-π-Lewis base catalysis.



Table 1 Optimisation of catalytic conditions for diastereodivergent [4 + 2] annulations^a

Entry	L	Solvent	Additive	Yield ^b (%)	dr ^c	ee ^d (%)
1	L1	Toluene	—	Trace	—	—
2	L2	Toluene	—	Trace	—	—
3	L3	Toluene	—	4a, 62	>19:1	75
4	L4	Toluene	—	4a, 82	>19:1	93
5	L5	Toluene	—	4a, 30	4:1	71
6	L6	Toluene	—	4a, 73	10:1	93
7	L7	Toluene	—	4a, 95	>19:1	98
8 ^e	L7	Toluene	—	4a, 95	>19:1	98
9 ^f	L7	Toluene	—	4a, 50	>19:1	98
10	L8	Toluene	—	Messy	—	—
11	L9	Toluene	—	Messy	—	—
12	L10	Toluene	—	5a, 92	<1:19	82
13	L11	Toluene	—	Trace	—	—
14	L10	THF	—	5a, 51	1:10	80
15	L10	Dioxane	—	5a, 35	1:11	82
16	L10	CHCl ₃	—	5a, 20	1:2	89
17	L10	Toluene	A1	5a, 33	<1:19	83
18	L10	Toluene	A2	5a, 76	<1:19	80
19	L10	Toluene	A3	5a, 75	<1:19	80
20 ^g	L10	Toluene	—	5a, 25	<1:19	82
21 ^h	L10	Toluene	—	5a, 56	<1:19	83

^a Unless noted otherwise, reactions were carried out with **1a** (0.1 mmol), **2a** (0.05 mmol), Pd₂(dba)₃ (5 mol%), L (20 mol%) in toluene (0.5 mL) at 60 °C for 36 h under Ar. ^b Yield of the isolated product. ^c The ratio of **4a**/**5a**, determined from ¹H NMR analysis of crude products. ^d Determined from HPLC analysis on a chiral stationary phase. ^e L7 (10 mol%). ^f With Pd₂(dba)₃ (2.5 mol%). ^g With L10 (10 mol%). ^h At 50 °C, for 72 h.

reaction mechanism.⁹ As illustrated in Scheme 1b, exclusive *endo*-selectivity was observed in the uncatalysed inverse-electron-demand Diels–Alder reaction between 1,3-cyclohexadiene **1a** and aurone-derived 1-azadiene **2a**,¹⁰ resulting in the formation of *cis*-fused polycyclic product **3a** in a moderate yield after heating the reaction mixture at 80 °C for 36 h. Recently, our group demonstrated that Pd⁰ could act as a π -Lewis base catalyst to increase the highest occupied molecular orbital (HOMO) energy of linear 1,3-dienes through η^2 -coordination, thus promoting asymmetric Friedel–Crafts-type vinyllogous addition to *N*-sulfonylimines enantioselectively.¹¹ We envisaged that the Pd⁰- π -Lewis base catalysis would facilitate the asymmetric assembly of 1,3-cyclohexadiene **1a** and 1-azadiene **2a** by generating the high-HOMO-energy complex **I**. The reaction of **1a** with 1-azadiene **2a** indeed was promoted at a lower temperature (60 °C) in the presence of catalytic amounts of Pd(PPh₃)₄; intriguingly, *endo-cis-3a* was produced in a low

yield, whereas diastereomeric *exo-cis* cycloadduct **4a** and unexpected *trans-5a* were predominantly produced (from ¹H NMR analysis).¹² These experimental results suggested that Pd⁰ might render 1,3-cyclohexadiene **1a** more nucleophilic upon π -Lewis base activation, which would reverse the synergistic cycloaddition to a cascade vinyllogous Michael addition and diastereodivergent allylic amination process with 1-azadiene **2a**, as proposed in Scheme 1c. In the current work, we carried out a detailed study of the diastereodivergent and asymmetric [4 + 2] annulations between cyclic 1,3-dienes and 1-azadienes *via* ligand-controlled Pd catalysis. These annulations furnished both *cis*- and *trans*-fused tetrahydro-pyridine frameworks, structures having potential biological relevance, in a switchable and enantioenriched manner.¹³

Results and discussion


Optimisation of conditions for the diastereodivergent [4 + 2] annulation reaction

As discussed above, using Pd(PPh₃)₄ successfully changed the reaction pathway of the reaction of 1,3-cyclohexadiene **1a** with 1-azadiene **2a** from a concerted Diels–Alder process into a stepwise tandem vinyllogous Michael addition/allylic amination sequence, making the potential diastereodivergent construction of both *cis*- and *trans*-fused cycloadducts possible when properly tuning the catalytic conditions. A series of chiral ligands in combination with Pd₂(dba)₃ were investigated in order to realise the diastereo-divergent [4 + 2] annulations asymmetrically. While commonly used *S*-BINAP **L1** and Trost's ligand **L2** failed to promote the conversions at 60 °C (Table 1, entries 1 and 2), using TADDOL-derived phosphoramidite ligand **L3** pleasingly provided chiral *exo-4a* in moderate yield and enantioselectivity with complete diastereocontrol (entry 3). Other types of phosphoramidite ligands, namely **L4**–**L7**, derived from different chiral backbones were also screened (entries 4–7), and **4a** was finally obtained as a single diastereomer in outstanding yield and enantioselectivity by using a SPINOL-based ligand **L7** (entry 7).¹⁴ High catalytic efficiency was still observed with lower ligand loadings (entry 8), but the yield was decreased significantly with 5 mol% palladium (entry 9). In order to switch the diastereoselectivity, more chiral ligands were investigated. While Tang's chiral P-based ligand **L8** and 1,2-aminoalcohol-derived ligand **L9** delivered the products as diastereomeric mixtures (entries 10 and 11),^{15,16} employing commercially available (*R,R*)-Me-DuPhos monoxide **L10** led to exclusive formation of *trans-5a* in an excellent yield with good enantiocontrol (entry 12). In order to further improve the enantioselectivity for **5a**, more reaction parameters involving ligands, solvents, additives and temperature were evaluated, but inferior results were generally observed (entries 13–21).^{17,18}


Substrate scope and limitations

With the optimised catalytic conditions in hand, we first investigated the substrate scope and limitations for asymmetric synthesis of *cis*-fused diastereomers **4** under the catalysis of Pd₂(dba)₃ and ligand **L7**. As summarised in Scheme 2a, an array






Scheme 2 Substrate scope and limitations of diastereodivergent [4 + 2] annulations. Unless noted otherwise, reactions were carried out with **1** (0.2 mmol, 2.0 equiv.), 1-azadiene **2** (0.1 mmol, 1.0 equiv.), Pd₂(dba)₃ (5 mol%), and L7 (10 mol%) or L10 (20 mol%) in toluene (1.0 mL) at 60 °C for 48 h under Ar.



Scheme 3 Investigation of more cyclic dienes or polyenes. (a) Reactions of cycloheptadiene **6**. (b) Reactions of cycloheptatriene **10**. (c) Reactions of cyclopentadiene **13**.





Scheme 4 Investigation of linear 1,3-dienes and 1-heterodienes. (a) Assembly of linear 1,3-diene and 1-azadiene 2a. (b) Investigation of linear electron-deficient heterodienes.

of *N*-tosyl 1-azadienes **2** bearing diverse aryl, heteroaryl, and even *tert*-butyl groups underwent the [4 + 2] annulations with 1,3-cyclohexadiene **1a** smoothly, affording the expected products **4b–4g** with excellent yields and stereoselectivity, even on a 1.0 mmol scale (for product **4a**). In addition, varying the substituents on the benzofuran ring and *N*-protecting group had minimal effect on the reactivity and stereoselectivity, as comparably good results were attained for products **4h–4j**. Moreover, diene partner **1b** bearing a 2-*n*-butyl group was also applicable, having reacted to form enantioenriched product **4k** in a moderate yield, whereas complex reaction profiles were observed with 2-phenyl-1,3-cyclohexadiene **1c** and 1-*n*-butyl-1,3-cyclohexadiene **1d**.

The substrate scope for the synthesis of *trans*-fused diastereomers **5** was investigated next. As outlined in Scheme 2b, this synthesis was observed to be relatively inefficient when Pd₂(dba)₃ in combination with L10 was used as the catalyst. The *trans*-fused products **5b–5i** were generally obtained in good yields and enantioselectivity but with exclusive

diastereoselectivity, whereas a significantly decreased yield and enantiocontrol were observed for alkyl-substituted product **5j**. And the alkyl-substituted 1-azadiene **2g** was not reactive. It should be noted that the optical purity levels of some products, such as **5d**, **5g** and **5h**, could be readily improved by subjecting them to simple recrystallisation (Scheme 2b, data in parentheses). Moreover, *ent*-**4a** and *ent*-**5a** could be effectively furnished by using the combination of Pd₂(dba)₃ with complementary ligands *ent*-L7 and *ent*-L10, respectively; thus four diastereomers could be smoothly produced just by tuning the ligands, demonstrating the versatility of the current method.

Additional types of cyclic dienes and even polyenes were investigated. As illustrated in Scheme 3a, 1,3-cycloheptadiene **6** could be successfully applied to diastereodivergent [4 + 2] annulations with 1-azadiene **2a** to produce *cis*-product **7** and *trans*-product **8** in moderate to good yields and stereoselectivity, by employing ligands L12 and L10, respectively. Interestingly, a β-H elimination, rather than *N*-allylic alkylation, occurred to



give adduct **9** in a moderate yield with fair enantioselectivity, when using TADDOL-derived phosphoramidite ligand **L3**; this result provided further support for the involvement of a stepwise process in the observed [4 + 2] reaction. Additionally, *cis*-fused cycloadduct **11** was obtained from cycloheptatriene **10** and 1-azadiene **2** with excellent enantioselectivity and moderate diastereoselectivity when using Pd/**L13** as the catalyst, whereas β -H elimination product **12** was delivered with moderate results when using Pd/**L14** (Scheme 3b). Furthermore, the assemblies of cyclopentadiene **13** and 1-azadienes **2** occurred successfully when Pd/**L7** was used as the catalyst, and *exo*-selective cycloadducts **14a–14c** were furnished with high enantioselectivity and moderate diastereoselectivity (Scheme 3c).

The current catalytic strategy could be further expanded to acyclic dienes, further enriching the structural diversity of the frameworks constructed. As depicted in Scheme 4a, diastereodivergent [4 + 2] annulations between linear terminal 1,3-diene **15** and 1-azadiene **2a** could be similarly realised *via* ligand-controlled palladium catalysis. Both *exo*- and *endo*-selective cycloadducts **16** and **17** were efficiently constructed when using ligands **L4** and **L15**, respectively, albeit with moderate enantioselectivity. Internal diene **18** exhibited higher reactivity with 1-azadiene **2a** when using Pd/**L10** as the catalyst, providing the *exo*-cycloadduct **19** in excellent yield and stereoselectivity, along with an inseparable regioisomer **20**. Nevertheless, a chemoselective intramolecular iodoetherification of **19** was further carried out to generate tetracyclic product **21** with exclusive diastereocontrol. Apart from cyclic 1-azadienes **2**, linear 2-*N*-tosyliminoacrylate **22** and 1-oxadiene **24** were also reliable partners in the assemblies with linear 1,3-dienes,^{14c} furnishing tetrahydropyridine product **23** and dihydropyran **25**, respectively, with moderate results. These experiments well verified the general compatibility of the π -Lewis base catalysis of Pd⁰ complexes for activating diene substrates, though some improvements remain to be made.

Conclusions

Taking advantage of the unique vinylogous activation feature of Pd⁰- π -Lewis base catalysis, we successfully reversed the process of the concerted and *endo*-selective hetero-Diels–Alder cycloaddition reaction between cyclic 1,3-diene and electron-deficient aurone-derived cyclic 1-azadienes into a stepwise cascade vinylogous Michael addition/allylic amination sequence. As a result, the formal *exo*-selective and *cis*-fused [4 + 2] annulation products with polycyclic architectures were efficiently constructed with moderate to excellent enantioselectivity and diastereoselectivity levels by using a chiral SPINOL-derived phosphoramidite ligand. Moreover, the switchable diastereodivergent synthesis of challenging *trans*-fused [4 + 2] frameworks was also successfully accomplished by employing commercially available (*R,R*)-Me-DuPhos monoxide ligand. In addition, the current Pd⁰- π -Lewis base catalysis was applicable to the assemblies for a variety of acyclic 1,3-dienes and 1-heterodienes, further enriching the structural diversity and versatility of relevant cycloadducts.

Data availability

The data that support the findings of this study are available in the ESI† or on request from the corresponding author.

Author contributions

All authors contributed to the writing of the manuscript and have given approval to the final version of the manuscript.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We are grateful for the financial support from the National Natural Science Foundation of China (21931006, 92156005, and 21921002) and the 111 project (B18035).

Notes and references

- For selected examples, see: (a) W. H. Brooks, W. C. Guida and K. G. Daniel, *Curr. Top. Med. Chem.*, 2011, **11**, 760–770; (b) K. Gandhi, U. Shah and S. Patel, *Curr. Drug Discovery Technol.*, 2020, **17**, 565–573.
- For selected reviews, see: (a) L. Lin and X. Feng, *Chem.–Eur. J.*, 2017, **23**, 6464–6482; (b) M. Bihani and J. C.-G. Zhao, *Adv. Synth. Catal.*, 2017, **359**, 534–575; (c) I. P. Beletskaya, C. Nájera and M. Yus, *Chem. Rev.*, 2018, **118**, 5080–5200; (d) X. Huo, G. Li, X. Wang and W. Zhang, *Angew. Chem., Int. Ed.*, 2022, e202210086.
- For selected examples, see: (a) X. Feng, Z. Zhou, R. Zhou, Q.-Q. Zhou, L. Dong and Y.-C. Chen, *J. Am. Chem. Soc.*, 2012, **134**, 19942–19947; (b) J. Lv, L. Zhang, S. Luo and J.-P. Cheng, *Angew. Chem., Int. Ed.*, 2013, **52**, 9786–9790; (c) Z.-Q. Rong, M. Wang, C. H. E. Chow and Y. Zhao, *Chem. – Eur. J.*, 2016, **22**, 9483–9487; (d) G. Zhan, M.-L. Shi, Q. He, W.-J. Lin, Q. Ouyang, W. Du and Y.-C. Chen, *Angew. Chem., Int. Ed.*, 2016, **55**, 2147–2151; (e) S. B. J. Kan, H. Maruyama, M. Akakura, T. Kano and K. Maruoka, *Angew. Chem., Int. Ed.*, 2017, **56**, 9487–9491; (f) D. Uraguchi, K. Yoshioka and T. Ooi, *Nat. Commun.*, 2017, **8**, 14793–14802.
- For selected examples, see: (a) B. M. Trost, N. Cramer and S. M. Silverman, *J. Am. Chem. Soc.*, 2007, **129**, 12396–12397; (b) M. Luparia, M. T. Oliveira, D. Audisio, F. Frébault, R. Goddard and N. Maulide, *Angew. Chem., Int. Ed.*, 2011, **50**, 12631–12635; (c) X. Hao, L. Lin, F. Tan, C. Yin, X. Liu and X. Feng, *ACS Catal.*, 2015, **5**, 6052–6056; (d) P. Zhou, X. Shao and S. J. Malcolmson, *J. Am. Chem. Soc.*, 2021, **143**, 13999–14008; (e) S. Krautwald, D. Sarlah, M. A. Schafroth and E. M. Carreira, *Science*, 2013, **340**, 1065–1068; (f) X. Jiang, J. J. Beiger and J. F. Hartwig, *J. Am. Chem. Soc.*, 2017, **139**, 87–90; (g) Y. Peng, X. Huo, Y. Luo, L. Wu and W. Zhang, *Angew. Chem., Int. Ed.*, 2021, **60**, 24941–24949; (h) X. Chang, X. Cheng, X.-T. Liu, C. Fu, W.-Y. Wang and C.-J. Wang, *Angew. Chem., Int. Ed.*, 2022, **61**, e202206517.



- 5 For selected examples, see: (a) K. L. Jensen, C. F. Weise, G. Dickmeiss, F. Morana, R. L. Davis and K. A. Jørgensen, *Chem. - Eur. J.*, 2012, **18**, 11913–11918; (b) B.-X. Liu, R.-J. Yan, W. Du and Y.-C. Chen, *Chin. J. Chem.*, 2022, **40**, 1185–1189.
- 6 X. Tian, C. Cassani, Y. Liu, A. Moran, A. Urakawa, P. Galzerano, E. Arce and P. Melchiorre, *J. Am. Chem. Soc.*, 2011, **133**, 17934–17941.
- 7 For selected examples, see: (a) S.-L. Shi, Z. L. Wong and S. L. Buchwald, *Nature*, 2016, **532**, 353–356; (b) D. Kaldre, I. Klose and N. Maulide, *Science*, 2018, **361**, 664–667.
- 8 (a) R. Gilmour, T. J. Prior, J. W. Burton and A. B. Holmes, *Chem. Commun.*, 2007, 3954–3956; (b) D. Belmessieri, A. de La Houpliere, E. D. D. Calder, J. E. Taylor and A. D. Smith, *Chem.-Eur. J.*, 2014, **20**, 9762–9769; (c) J. Zhu, Y. Liang, L. Wang, Z.-B. Zheng, K. N. Houk and Y. Tang, *J. Am. Chem. Soc.*, 2014, **136**, 6900–6903; (d) H. Huang, S. Konda and J. C.-G. Zhao, *Angew. Chem., Int. Ed.*, 2016, **55**, 2213–2216; (e) X. Wu, Z. Chen, Y.-B. Bai and V. M. Dong, *J. Am. Chem. Soc.*, 2016, **138**, 12013–12016.
- 9 For selected examples, see: (a) Y. Zhu, X. Chen, M. Xie, S. Dong, Z. Qiao, L. Lin, X. Liu and X. Feng, *Chem. - Eur. J.*, 2010, **16**, 11963–11968; (b) X.-G. Si, Z.-M. Zhang, C.-G. Zheng, Z.-T. Li and Q. Cai, *Angew. Chem., Int. Ed.*, 2020, **59**, 18412–18417; (c) M.-M. Xu, L. Yang, K. Tan, X. Chen, Q.-T. Lu, K.-N. Houk and Q. Cai, *Nat. Catal.*, 2021, **4**, 892–900; (d) K. Matsui, K. Toh, M. Hatano and K. Ishihara, *Org. Lett.*, 2022, **24**, 6483–6488.
- 10 For selected examples, see: (a) Q. Deng and X. Meng, *Chem.-Asian J.*, 2020, **15**, 2838–2853; (b) L.-C. Yang, Z.-Q. Rong, Y.-N. Wang, Z. Y. Tan, M. Wang and Y. Zhao, *Angew. Chem., Int. Ed.*, 2017, **56**, 2927–2931; (c) H. Ni, X. Tang, W. Zheng, W. Yao, N. Ullah and Y. Lu, *Angew. Chem., Int. Ed.*, 2017, **56**, 14222–14226; (d) B. M. Trost and Z. Zuo, *Angew. Chem., Int. Ed.*, 2021, **60**, 5806–5810.
- 11 For selected examples, see: (a) B.-X. Xiao, B. Jiang, R.-J. Yan, J.-X. Zhu, K. Xie, X.-Y. Gao, Q. Ouyang, W. Du and Y.-C. Chen, *J. Am. Chem. Soc.*, 2021, **143**, 4809–4816; (b) X.-X. Yang, R.-J. Yan, G.-Y. Ran, C. Chen, J.-F. Yue, X. Yan, Q. Ouyang, W. Du and Y.-C. Chen, *Angew. Chem., Int. Ed.*, 2021, **60**, 26762–26768; (c) X.-X. Yang, X.-L. Zhao, Q. Ouyang, W. Du and Y.-C. Chen, *Org. Chem. Front.*, 2022, **9**, 1364–1369; (d) J.-X. Zhu, Z.-C. Chen, W. Du and Y.-C. Chen, *Angew. Chem., Int. Ed.*, 2022, **61**, e202200880; (e) X.-L. Liu, Y.-Y. Zhang, L. Li, L.-Q. Tan, Y.-A. Huang, J.-A. Ma and J.-B. Peng, *Org. Lett.*, 2022, **24**, 6692–6696.
- 12 For selected *exo*-Diels–Alder reactions, see: (a) M. Hatano, T. Mizuno, A. Izumiseki, R. Usami, T. Asai, M. Akakura and K. Ishihara, *Angew. Chem., Int. Ed.*, 2011, **50**, 12189–12192; (b) M. Hatano and K. Ishihara, *Chem. Commun.*, 2012, **48**, 4273–4283; (c) M. Hatano, T. Sakamoto, T. Mizuno, Y. Goto and K. Ishihara, *J. Am. Chem. Soc.*, 2018, **140**, 16253–16263; (d) Y.-h. Lam, P. H.-Y. Cheong, J. B. Mata, S. J. Stanway, V. Gouverneur and K. N. Houk, *J. Am. Chem. Soc.*, 2009, **131**, 1947–1957.
- 13 For selected examples, see: (a) J. D. Scott and R. M. Williams, *Chem. Rev.*, 2002, **102**, 1669–1730; (b) C.-L. Yang, C.-H. Tseng, Y.-L. Chen, C.-M. Lu, C.-L. Kao, M.-H. Wu and C.-C. Tzeng, *Eur. J. Med. Chem.*, 2010, **45**, 602–607.
- 14 J.-H. Xie and Q.-L. Zhou, *Acc. Chem. Res.*, 2008, **41**, 581–593.
- 15 G. Xu, C. H. Senanayake and W. Tang, *Acc. Chem. Res.*, 2019, **52**, 1101–1112.
- 16 C. Chen, X.-X. Yang, Z. Zhao, B. Han, W. Du and Y.-C. Chen, *Chem. Commun.*, 2022, **58**, 5502–5505.
- 17 For more condition screenings, see the ESI†
- 18 For more control experiments and proposed ligand-based stereocontrol models, see the ESI†.

